EssexBio

Essex-Bio Group

简繁 EN

ANNOUNCEMENTS & SHAREHOLDER INFORMATION

Normative Disclosure, Honest Communication

Date

Title

File

Times

2021-02-22

NSIDE INFORMATION FURTHER UPDATES IN RELATION TO CO-DEVELOPMENT AGREEMENT - U.S. FDA SECOND PHASE 3 CLINICAL TRIAL ("VISTA-2") IN DRY EYE DISEASE

1642

2021-02-22

NEXT DAY DISCLOSURE RETURN

1787

2021-02-02

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2021

1698

2021-01-29

VOLUNTARY ANNOUNCEMENT UPDATE IN RELATION TO THE CO-DEVELOPMENT OF THE LICENSED PRODUCT WITH HENLIUS RELATING TO THE TREATMENT OF EXUDATIVE (WET) AGE-RELATED MACULAR DEGENERATION

1762

2021-01-29

NEXT DAY DISCLOSURE RETURN

1739

2021-01-28

NEXT DAY DISCLOSURE RETURN

1697

2021-01-27

NEXT DAY DISCLOSURE RETURN

1752

2021-01-26

NEXT DAY DISCLOSURE RETURN

1785

2021-01-22

NEXT DAY DISCLOSURE RETURN

1733

2021-01-20

NEXT DAY DISCLOSURE RETURN

1772

2021-01-19

NEXT DAY DISCLOSURE RETURN

1657

2021-01-18

NEXT DAY DISCLOSURE RETURN

1718

2021-01-15

NEXT DAY DISCLOSURE RETURN

1674

2021-01-14

NEXT DAY DISCLOSURE RETURN

1766

2021-01-13

NEXT DAY DISCLOSURE RETURN

1756

2021-01-12

NEXT DAY DISCLOSURE RETURN

1763

2021-01-11

NEXT DAY DISCLOSURE RETURN

1708

2021-01-08

NEXT DAY DISCLOSURE RETURN

1719

2021-01-07

NEXT DAY DISCLOSURE RETURN

1776

2021-01-05

NEXT DAY DISCLOSURE RETURN

1685

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT